| This research studies the feasibility of Needle-free devices for the administration of Adalimumab and other possible drug candidates including vaccines, antibodies and peptides for the needle-free system evaluating the benefits of using Needle-free devices. Research about the properties of this candidates, traditional injection, gauge sizes, transdermal patches, iontophoresis, needle-free jet injector, Lorentz-Force actuator leads to the conclusion that Adalimumab and many other therapeutic agents are compatible with such technologies. Comparison of the different Needle-free market products and their selling points suggest it is feasible to implement the use of this technology for delivery of macromolecule based drugs. |
